

Kalijn Bol

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9175553/publications.pdf>

Version: 2024-02-01

36
papers

2,107
citations

331538

21
h-index

377752

34
g-index

36
all docs

36
docs citations

36
times ranked

3284
citing authors

#	ARTICLE	IF	CITATIONS
1	Personalized therapy with peptide-based neoantigen vaccine (EVX-01) including a novel adjuvant, CAF [®] 09b, in patients with metastatic melanoma. <i>Oncolimmunology</i> , 2022, 11, 2023255.	2.1	18
2	Immunological responses to adjuvant vaccination with combined CD1 ^{c<sup>+</sup>} myeloid and plasmacytoid dendritic cells in stage III melanoma patients. <i>Oncolimmunology</i> , 2022, 11, .	2.1	14
3	Paired primary and metastatic lesions of patients with ipilimumab-treated melanoma: high variation in lymphocyte infiltration and HLA-ABC expression whereas tumor mutational load is similar and correlates with clinical outcome. , 2022, 10, e004329.		15
4	Trial watch: Dendritic cell (DC)-based immunotherapy for cancer. <i>Oncolimmunology</i> , 2022, 11, .	2.1	54
5	The ESSO core curriculum committee update on surgical oncology. <i>European Journal of Surgical Oncology</i> , 2021, 47, e1-e30.	0.5	6
6	Qualitative Analysis of Tumor-Infiltrating Lymphocytes across Human Tumor Types Reveals a Higher Proportion of Bystander CD8+ T Cells in Non-Melanoma Cancers Compared to Melanoma. <i>Cancers</i> , 2020, 12, 3344.	1.7	19
7	Genetic Biomarkers in Melanoma of the Ocular Region: What the Medical Oncologist Should Know. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5231.	1.8	15
8	Response and survival of metastatic melanoma patients treated with immune checkpoint inhibition for recurrent disease on adjuvant dendritic cell vaccination. <i>Oncolimmunology</i> , 2020, 9, 1738814.	2.1	13
9	Autologous monocyte-derived DC vaccination combined with cisplatin in stage III and IV melanoma patients: a prospective, randomized phase 2 trial. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 477-488.	2.0	42
10	Human pDCs Are Superior to cDC2s in Attracting Cytolytic Lymphocytes in Melanoma Patients Receiving DC Vaccination. <i>Cell Reports</i> , 2020, 30, 1027-1038.e4.	2.9	29
11	ASO Author Reflections: Frequent Relapses Prior to the Start of Adjuvant Therapy in Stage IIIB/C Melanoma. <i>Annals of Surgical Oncology</i> , 2019, 26, 3953-3954.	0.7	2
12	Real-World Impact of Immune Checkpoint Inhibitors in Metastatic Uveal Melanoma. <i>Cancers</i> , 2019, 11, 1489.	1.7	37
13	The clinical application of cancer immunotherapy based on naturally circulating dendritic cells. , 2019, 7, 109.		129
14	Early Recurrence in Completely Resected IIIB and IIIC Melanoma Warrants Restaging Prior to Adjuvant Therapy. <i>Annals of Surgical Oncology</i> , 2019, 26, 3945-3952.	0.7	24
15	Health-related quality of life analysis in stage III melanoma patients treated with adjuvant dendritic cell therapy. <i>Clinical and Translational Oncology</i> , 2019, 21, 774-780.	1.2	7
16	Dendritic Cell Cancer Therapy: Vaccinating the Right Patient at the Right Time. <i>Frontiers in Immunology</i> , 2018, 9, 2265.	2.2	107
17	Direct inhibition of STAT signaling by platinum drugs contributes to their anti-cancer activity. <i>Oncotarget</i> , 2017, 8, 54434-54443.	0.8	13
18	Immune-related Adverse Events of Dendritic Cell Vaccination Correlate With Immunologic and Clinical Outcome in Stage III and IV Melanoma Patients. <i>Journal of Immunotherapy</i> , 2016, 39, 241-248.	1.2	26

#	ARTICLE	IF	CITATIONS
19	The use of dendritic cell vaccinations in melanoma: where are we now?. <i>Melanoma Management</i> , 2016, 3, 247-250.	0.1	3
20	Dendritic Cell–Based Immunotherapy: State of the Art and Beyond. <i>Clinical Cancer Research</i> , 2016, 22, 1897-1906.	3.2	295
21	T-cell Landscape in a Primary Melanoma Predicts the Survival of Patients with Metastatic Disease after Their Treatment with Dendritic Cell Vaccines. <i>Cancer Research</i> , 2016, 76, 3496-3506.	0.4	33
22	Adjuvant Dendritic Cell Vaccination in High-Risk Uveal Melanoma. <i>Ophthalmology</i> , 2016, 123, 2265-2267.	2.5	44
23	Adjuvant dendritic cell vaccination induces tumor-specific immune responses in the majority of stage III melanoma patients. <i>Oncolmmunology</i> , 2016, 5, e1191732.	2.1	17
24	Ipilimumab administered to metastatic melanoma patients who progressed after dendritic cell vaccination. <i>Oncolmmunology</i> , 2016, 5, e1201625.	2.1	21
25	Favorable overall survival in stage III melanoma patients after adjuvant dendritic cell vaccination. <i>Oncolmmunology</i> , 2016, 5, e1057673.	2.1	67
26	Prophylactic vaccines are potent activators of monocyte-derived dendritic cells and drive effective anti-tumor responses in melanoma patients at the cost of toxicity. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 327-339.	2.0	50
27	Effective Clinical Responses in Metastatic Melanoma Patients after Vaccination with Primary Myeloid Dendritic Cells. <i>Clinical Cancer Research</i> , 2016, 22, 2155-2166.	3.2	211
28	Intranodal vaccination with mRNA-optimized dendritic cells in metastatic melanoma patients. <i>Oncolmmunology</i> , 2015, 4, e1019197.	2.1	55
29	Long Overall Survival After Dendritic Cell Vaccination in Metastatic Uveal Melanoma Patients. <i>American Journal of Ophthalmology</i> , 2014, 158, 939-947.e5.	1.7	53
30	Targeting CD4+ T-Helper Cells Improves the Induction of Antitumor Responses in Dendritic Cell–Based Vaccination. <i>Cancer Research</i> , 2013, 73, 19-29.	0.4	131
31	Importance of helper T-cell activation in dendritic cell-based anticancer immunotherapy. <i>Oncolmmunology</i> , 2013, 2, e24440.	2.1	11
32	Naturally circulating dendritic cells to vaccinate cancer patients. <i>Oncolmmunology</i> , 2013, 2, e23431.	2.1	27
33	Vaccination with mRNA-Electroporated Dendritic Cells Induces Robust Tumor Antigen-Specific CD4+ and CD8+ T Cells Responses in Stage III and IV Melanoma Patients. <i>Clinical Cancer Research</i> , 2012, 18, 5460-5470.	3.2	86
34	Skin-Test Infiltrating Lymphocytes Early Predict Clinical Outcome of Dendritic Cell–Based Vaccination in Metastatic Melanoma. <i>Cancer Research</i> , 2012, 72, 6102-6110.	0.4	50
35	Prognostic significance and mechanism of Treg infiltration in human brain tumors. <i>Journal of Neuroimmunology</i> , 2010, 225, 195-199.	1.1	180
36	Regulatory T cells and the PD-L1/PD-1 pathway mediate immune suppression in malignant human brain tumors. <i>Neuro-Oncology</i> , 2009, 11, 394-402.	0.6	203